Amla therapy as a potential modulator of Alzheimer's disease risk factors and physiological change

Document Type

Journal Article

Publication Title

Journal of Alzheimer's Disease

Publisher

IOS Press

School

Centre of Excellence for Alzheimer’s Disease Research and Care / School of Medical and Health Sciences

RAS ID

32095

Funders

Edith Cowan University, ECU

BrightFocus Foundation

National Health and Medical Research Council, NHMRC

Curtin University of Technology

Grant Number

NHMRC Numbers : APP1105698, APP1045507, APP1107109

Comments

Teimouri, E., Rainey-Smith, S. R., Bharadwaj, P., Verdile, G., & Martins, R. N. (2020). Amla therapy as a potential modulator of Alzheimer's disease risk factors and physiological change. Journal of Alzheimer's Disease, 74(3), 713-733. https://doi.org/10.3233/JAD-191033

Abstract

There is currently no effective treatment for Alzheimer's disease (AD), the most common form of dementia. It has been proposed, however, that a modest delay in onset can significantly reduce the number of cases. Thus, prevention and intervention strategies are currently the focus of much research. In the search for compounds that potentially confer benefit, the Amla fruit and its extracts have drawn attention. Amla preparations have been used for centuries in traditional Indian medicine systems such as Ayurveda, with various parts of the plant used to treat a variety of diseases. Here we review many animal-based studies, and some clinical trials, which have shown that Amla, and its extracts, exert many positive effects on dyslipidemia, hyperglycemia, inflammation, oxidative stress, apoptosis, and autophagy, that contribute to AD risk. Collectively, this evidence suggests that Amla may be of value as part of an effective disease-delaying treatment for AD. © 2020-IOS Press and the authors. All rights reserved.

DOI

10.3233/JAD-191033

Access Rights

subscription content

Link to Full Text

Share

 
COinS